William E. Rote, Chief Research Officer at Travere Therapeutics ($TVTX), sold about $2.9 million in company shares across three open market transactions in the past year. His latest sale was on February 3, 2026. These sales rank 2,794th out of 11,678 insiders, below the average of $8.6 million per insider over roughly six trades. Rote made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 31, 2026 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | Chief Research Officer | A | Employee stock option (right to buy) | 53570 | $0.00 | 53,570.0000 | 89,211,813 | 9999.99% | 0.06% |
| Feb. 3, 2026 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | Chief Research Officer | S | Common Stock | 12446 | $32.87 | 109,087.0000 | 89,211,813 | 10.24% | 0.01% |
| Jan. 31, 2026 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | Chief Research Officer | A | Common Stock | 20090 | $0.00 | 121,533.0000 | 89,211,813 | 19.80% | 0.02% |
| Dec. 24, 2025 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | Chief Research Officer | M | Employee stock option (right to buy) | 60000 | $0.00 | 0.0000 | 102,618,560 | 100.00% | 0.06% |
| Dec. 24, 2025 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | Chief Research Officer | S | Common Stock | 60000 | $40.10 | 101,443.0000 | 102,618,560 | 37.16% | 0.06% |
| Dec. 24, 2025 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | Chief Research Officer | M | Common Stock | 60000 | $20.61 | 161,443.0000 | 102,618,560 | 59.15% | 0.06% |
| May 2, 2025 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | Chief Research Officer | M | Common Stock | 4920 | $0.00 | 103,439.0000 | 78,888,861 | 4.99% | 0.01% |
| May 5, 2025 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | Chief Research Officer | S | Common Stock | 3198 | $21.05 | 100,241.0000 | 78,888,861 | 3.09% | 0.00% |
| May 2, 2025 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | Chief Research Officer | M | Performance-based restricted stock units | 4920 | $0.00 | 4,920.0000 | 78,888,861 | 50.00% | 0.01% |
| Feb. 10, 2025 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | M | Common Stock | 8000 | $0.00 | 103,719.0000 | 78,888,861 | 8.36% | 0.01% |
| Feb. 12, 2025 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | S | Common Stock | 5200 | $23.53 | 98,519.0000 | 78,888,861 | 5.01% | 0.01% |
| Feb. 10, 2025 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | M | Performance-based restricted stock units | 8000 | $0.00 | 0.0000 | 78,888,861 | 100.00% | 0.01% |
| Jan. 31, 2025 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | A | Employee stock option (right to buy) | 58000 | $0.00 | 58,000.0000 | 78,888,861 | 9999.99% | 0.07% |
| Jan. 31, 2025 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | A | Common Stock | 21500 | $0.00 | 104,670.0000 | 78,888,861 | 25.85% | 0.03% |
| Feb. 3, 2025 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | S | Common Stock | 8951 | $19.78 | 95,719.0000 | 78,888,861 | 8.55% | 0.01% |
| Jan. 22, 2025 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | S | Common Stock | 2437 | $19.46 | 83,170.0000 | 78,888,861 | 2.85% | 0.00% |
| Sept. 5, 2024 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | A | Common Stock | 6750 | $0.00 | 88,842.0000 | 74,267,418 | 8.22% | 0.01% |
| Sept. 9, 2024 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | S | Common Stock | 4387 | $11.52 | 84,455.0000 | 74,267,418 | 4.94% | 0.01% |
| Feb. 1, 2024 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | S | Common Stock | 2590 | $8.86 | 80,720.0000 | 74,267,418 | 3.11% | 0.00% |
| Jan. 31, 2024 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | A | Common Stock | 25000 | $0.00 | 85,484.0000 | 74,267,418 | 41.33% | 0.03% |
| Feb. 1, 2024 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | S | Common Stock | 2174 | $8.53 | 83,310.0000 | 74,267,418 | 2.54% | 0.00% |
| Jan. 31, 2024 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | A | Employee stock option (right to buy) | 65000 | $0.00 | 65,000.0000 | 74,267,418 | 9999.99% | 0.09% |
| Jan. 23, 2024 | Travere Therapeutics, Inc. | $TVTX | ROTE WILLIAM E. | SENIOR VICE PRESIDENT, R&D | S | Common Stock | 2062 | $8.96 | 60,484.0000 | 74,267,418 | 3.30% | 0.00% |